Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661201 · ClinicalTrials.gov registry record · Phase 1
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
A Phase 1 study of Solid Tumor and KRAS Mutation-Related Tumors, sponsored by Georgetown University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05661201: Recruiting Phase 1 study of Solid Tumor and KRAS Mutation-Related Tumors, sponsored by Georgetown University.
NCT05661201 is a Phase 1 study of Solid Tumor and KRAS Mutation-Related Tumors that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 24 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05661201, a Phase 1 study of Solid Tumor and KRAS Mutation-Related Tumors, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Primary Outcome
Safety and tolerability of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG NEROFE
Study Locations (1)
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT05661201 shows while recruiting
NCT05661201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Doxorubicin is the first listed.
NCT05661201 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05661201 about?
NCT05661201 is a clinical study titled "NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors". The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the...
What is the current status of trial NCT05661201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-04-12. Estimated completion is 2027-01.
What conditions does trial NCT05661201 study?
This clinical trial studies the following conditions: Solid Tumor, KRAS Mutation-Related Tumors.
What interventions are being tested in trial NCT05661201?
The interventions under investigation include: Doxorubicin (DRUG), NEROFE (DRUG).
Who is sponsoring clinical trial NCT05661201?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05661201 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05661201's enrollment target sits among peer trials
24 170th of 196 higher than 24 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI